請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67445
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王繼娟(Chi-Chuan Wang) | |
dc.contributor.author | Tsai-Ling Wu | en |
dc.contributor.author | 吳采玲 | zh_TW |
dc.date.accessioned | 2021-06-17T01:32:31Z | - |
dc.date.available | 2022-08-01 | |
dc.date.copyright | 2017-09-13 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-02 | |
dc.identifier.citation | 1. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015; 386(9996): 896-912.
2. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50(5): 1323-6. 3. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23(2): 82-5. 4. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000; 15(5): 873-8. 5. Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 2010; 25(10): 1357-63. 6. Ossola B, Schendzielorz N, Chen SH, et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology 2011; 61(4): 574-82. 7. Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 1994; 43: 91-104. 8. Weller M, Finiels-Marlier F, Paul SM. NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 1993; 613(1): 143-8. 9. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6): 525-35. 10. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Movement Disorders 1987; 2(2): 73-91. 11. Liu WM, Wu RM, Lin JW, Liu YC, Chang CH, Lin CH. Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study. J Formos Med Assoc 2016; 115(7): 531-8. 12. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014; 29(13): 1583-90. 13. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30(12): 1591-601. 14. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19(9): 1020-8. 15. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. The Lancet Neurology; 8(5): 464-74. 16. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40(10): 1529-34. 17. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord 2013; 28(5): 668-70. 18. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 2009; 73(3): 206-12. 19. Rajput AH, Pahwa R, Pahwa P, Rajput A. Prognostic significance of the onset mode in parkinsonism. Neurology 1993; 43(4): 829-30. 20. van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 2010; 25(8): 969-78. 21. van Rooden SM, Colas F, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011; 26(1): 51-8. 22. Thenganatt M, Jankovic J. Parkinson disease subtypes. JAMA Neurology 2014; 71(4): 499-504. 23. Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B. Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? Philos Trans R Soc Lond B Biol Sci 2015; 370(1672). 24. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013; 20(1): 5-15. 25. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. The Cochrane database of systematic reviews 2003; (2): Cd003735. 26. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. The Cochrane database of systematic reviews 2003; (1): Cd003468. 27. Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson's disease. Eur J Neurol 2009; 16(4): 450-6. 28. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311(16): 1670-83. 29. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011; 26 Suppl 3: S2-41. 30. Guo YJ, Liao YC, Lin CH, Chang MH. Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan. PLoS One 2014; 9(9): e107465. 31. Stewart Factor, Weiner W. Parkinson's Disease: Diagnosis & Clinical Management : Second Edition. 2 ed: Demos medical; 2008. 32. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2010; 16(8): 490-7. 33. Putterman DB, Munhall AC, Kozell LB, Belknap JK, Johnson SW. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. The Journal of pharmacology and experimental therapeutics 2007; 323(1): 277-84. 34. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005; 20 Suppl 11: S11-6. 35. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008; 23 Suppl 3: S580-4. 36. Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013; 28(8): 1064-71. 37. Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain 2014; 137(Pt 10): 2731-42. 38. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. The Lancet 2002; 359(9317): 1589-98. 39. Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Journal of neurology 2000; 247 Suppl 2: Ii36-42. 40. Gardoni F, Picconi B, Ghiglieri V, et al. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. The Journal of neuroscience : the official journal of the Society for Neuroscience 2006; 26(11): 2914-22. 41. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56(11): 1383-6. 42. Carta AR, Mulas G, Bortolanza M, et al. l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? Eur J Neurosci 2017; 45(1): 73-91. 43. Barnum CJ, Eskow KL, Dupre K, Blandino P, Jr., Deak T, Bishop C. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neuroscience 2008; 156(1): 30-41. 44. Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE, et al. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiol Dis 2015; 73: 377-87. 45. Janelidze S, Lindqvist D, Francardo V, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology 2015; 85(21): 1834-42. 46. Cenci MA, Lindgren HS. Advances in understanding l-DOPA-induced dyskinesia. Curr Opin Neurobiol 2007; 17(6): 665-71. 47. Jansen EN. Clozapine in the treatment of tremor in Parkinson's disease. Acta neurologica Scandinavica 1994; 89(4): 262-5. 48. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. The New England journal of medicine 1993; 329(3): 162-7. 49. Merello M, Damas IT, Obeso JA. Features and Mechanisms of Diphasic Dyskinesia in Parkinson’s Disease. In: Fox SH, Brotchie JM, eds. Levodopa-Induced Dyskinesia in Parkinson's Disease. London: Springer London; 2014: 135-46. 50. Katzenschlager R. Pharmacological Treatment Options for Levodopa-Induced Dyskinesia. In: Fox SH, Brotchie JM, eds. Levodopa-Induced Dyskinesia in Parkinson's Disease. London: Springer London; 2014: 69-88. 51. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13(2): 141-9. 52. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46(6): 1551-6. 53. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10(11): 1387-94. 54. Rojas P, Altagracia M, Kravsov J, Rios C. Partially protective effect of amantadine in the MPTP model of Parkinson's disease. Proc West Pharmacol Soc 1992; 35: 33-5. 55. Sullivan A, O´SQªKeeffe G. Neurotrophic factor therapy for Parkinson's disease: past, present and future. Neural Regeneration Research 2016; 11(2): 205-7. 56. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat Disord 2012; 18, Supplement 1: S210-S2. 57. Mulas G, Espa E, Fenu S, et al. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease. Exp Neurol 2016; 286: 83-92. 58. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme q10 in early parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 2002; 59(10): 1541-50. 59. Olanow CW, Rascol O, Hauser R, et al. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. N Engl J Med 2009; 361(13): 1268-78. 60. Poewe W. The natural history of Parkinson's disease. J Neurol 2006; 253 Suppl 7: Vii2-6. 61. Wei YJ, Palumbo FB, Simoni-Wastila L, et al. Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population. Value Health 2014; 17(2): 196-204. 62. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behavioral Research 2011; 46(3): 399-424. 63. Cohen J. The statistical power of abnormal-social psychological research: a review. J Abnorm Soc Psychol 1962; 65: 145-53. 64. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. The Lancet Neurology 2006; 5(4): 355-63. 65. Lücking CB, Dürr A, Bonifati V, et al. Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene. N Engl J Med 2000; 342(21): 1560-7. 66. Valente EM, Salvi S, Ialongo T, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56(3): 336-41. 67. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 1995; 293(3): 267-70. 68. Bortolanza M, Cavalcanti-Kiwiatkoski R, Padovan-Neto FE, et al. Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiol Dis 2015; 73: 377-87. 69. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57(2): 168-75. 70. Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol 2015; 11(1): 25-40. 71. Ebadi M, Sharma S, Shavali S, El Refaey H. Neuroprotective actions of selegiline. J Neurosci Res 2002; 67(3): 285-9. 72. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996; 39(1): 37-45. 73. Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early Parkinson's disease. The Cochrane database of systematic reviews 2005; (3): Cd004898. 74. Calabresi P, Filippo MD, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. The Lancet Neurology 2010; 9(11): 1106-17. 75. Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014; 384(9949): 1196-205. 76. Relja M. De-novo Amantadine Treatment Delays Onset of Dyskinesias in Patients with Parkinson Disease (I3-5A). Neurology 2015; 84(14 Supplement). 77. Jahangirvand A, Rajput A. Early Amantadine Treatment Does Not Delay Onset of Dyskinesias in Parkinson's Disease (P02.080). Neurology 2013; 80(7 Supplement): P02.080. 78. Nicoletti A, Mostile G, Nicoletti G, et al. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease. J Neurol 2016; 263(5): 888-94. 79. Zhang Y-h, Tang B-s, Song C-y, et al. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia. Neurosci Lett 2013; 556: 109-12. 80. Kipfer S, Stephan MA, Schüpbach W, Ballinari P, Kaelin-Lang A. Resting tremor in parkinson disease: A negative predictor of levodopa-induced dyskinesia. Arch Neurol 2011; 68(8): 1037-9. 81. Santos-Lobato B, Capelari M, Novaretti N, et al. Tremor-dominant clinical phenotype is associated with low risk of levodopa-induced dyskinesia in Parkinson's Disease. Mov Disord 2017; 32: 2-3. 82. Schumacher-Schuh A, Drumond F, Leal J, Dotto M, Machado S, Rieder C. Tremor as the first symptom reported by Parkinson's disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia. Mov Disord 2017; 32: 738-40. 83. Kadastik-Eerme L, Taba N, Asser T, Taba P. Factors associated with occurrence of motor complications among Parkinson's disease patients with levodopa treatment in Estonia. Mov Disord 2017; 32: 738. 84. Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson's disease cohort. Eur J Neurol 2016; 23(2): 304-12. 85. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003; 60(4): 601-5. 86. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67(9): 1612-7. 87. Fishman PS. Paradoxical aspects of parkinsonian tremor. Mov Disord 2008; 23(2): 168-73. 88. Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naive Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. Journal of neural transmission (Vienna, Austria : 1996) 2008; 115(5): 721-9. 89. Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain 2012; 135(Pt 11): 3206-26. 90. Kaasinen V, Kinos M, Joutsa J, Seppänen M, Noponen T. Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson’s disease. Eur J Nucl Med Mol Imaging 2014; 41(10): 1931-7. 91. Benarroch EE. Serotonergic modulation of basal ganglia circuits: complexity and therapeutic opportunities. Neurology 2009; 73(11): 880-6. 92. Naoi M, Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease. Expert Rev Neurother 2009; 9(8): 1233-50. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67445 | - |
dc.description.abstract | 研究背景
目前認為N-甲基-D-天門冬胺酸受體過激與多巴胺神經逐漸的死亡是造成左旋多巴誘發之異動症的兩項重要病理原因,近期有臨床前研究指出,amantadine除了具有抑制N-甲基-D-天門冬胺酸受體的作用,亦可透過抑制發炎反應達到保護多巴胺神經的作用,故此研究旨在探討巴金森病人早期使用amantadine與其異動症發病時間的相關性。 研究方法 本研究為一回溯性的世代研究,利用台大醫院資料庫2009年7月1日至2016年10月31日作為資料來源,欲納入具有主診斷為巴金森氏症的病患。為評估amantadine是否在不同動作表現型皆具有作用,故Antciholinergics以及MAOBIs將分別在世代一以及世代二作為amantadine的對照組。資料將會以界標分析 (Landmark analysis) 加上意向分析處理,以確保兩個世代有足夠的人數以及減少長期追蹤下的分類錯誤,此外,異動症的風險將會以權重後的Cox比例分險模式去統計。 研究結果 我們分別在世代一中的6個月界標納入741位病人、12個月界標納入641位病人以及18個月界標納入522位病人;世代二中的6個月界標則納入711位病人、12個月界標納入616位病人以及18個月界標納入491位病人。而經過傾向分數 (Propensity score) 加權後,世代一中的兩組其基礎特性相當,然而在世代二仍是存在些許的不平衡。在六個月界標中無事件的病人,amantadine相較於anticholinergics以及MAOBIs其在異動症的風險各別降低了28% (adjusted hazard ratio, 0.72; 95% CI 0.53–0.97)與39% (adjusted hazard ratio,0.61; 95% CI 0.44–0.83); 然而在12個月以及18個月界標中無事件的病人,世代一顯示兩組並無統計上差別,但在世代二amantadine相較於MAOBIs則是在兩個界標分析中皆具有顯著降低異動症風險的作用,其12個月界標分析的風險比為0.52 (95% CI 0.37-0.73),而在18個月界標分析的風險比則為0.45 (95% 0.31-0.64)。 結論 此為第一個回溯性研究指出早期使用amantadine相較於anticholinergics或是MAOBIs具有降低巴金森病人異動症風險的相關性,然而,amantadine服藥多久與其降低異動症的風險比例則需由未來設計良好的臨床試驗來進一步釐清。 | zh_TW |
dc.description.abstract | Background
Hyperactivity of N-Methyl-D-Aspartate (NMDA) receptor and progressive loss of dopaminergic neuron play crucial role in developing levodopa-induced dyskinesia (LID). Aside from blocking the NMDA receptor, recent preclinical study suggests that amantadine could protect the dopaminergic neurons through modulating the neuroinflammatory response. This study aimed to examine the association between early treatment with amantadine and the onset of LID in patient with idiopathic Parkinson’s disease. Methods We conducted a retrospective cohort study at National Taiwan University Hospital between July 1, 2009 and October 31, 2016. Patients with a primary diagnosis of idiopathic Parkinson’s disease were included in the study. To assess the effect of amantadine across different clinical phenotypes, anticholinergics and monoamine oxidase type B inhibitors (MAOBIs) were respectively selected as the active comparators respectively in the cohort 1 and cohort 2. Landmark analysis plus intention-to-treat approach were applied to ensure adequate sample size and eliminate misclassification in the long-term follow-up. The risk of LID was analyzed by the weighted Cox proportional hazard model. Results We include respectively 741 patients at 6-month landmark, 641 patients at 12-month landmark, and 522 patients at 18-month landmark in the cohort 1, and there were respectively 711 patients at 6-month landmark, 616 patients at 12-month landmark, and 491 patients at 18-month landmark in the cohort 2. After propensity score weighting, baseline characteristics were comparable at each landmark in the cohort 1. However, a few covariates still exist small differences in the cohort 2. Among patients who were event-free at 6-month landmark, amantadine had a respectively 28% (adjusted hazard ratio, 0.72; 95% CI 0.53–0.97) and 39% (adjusted hazard ratio,0.61; 95% CI 0.44–0.83) risk reduction on LID compared to anticholinergics and MAOBIs. No differences were found among patients who were event-free at the 12-month and 18-month landmarks in the cohort 1. However, amantadine significantly reduced the risk of LID among patients who were event-free at the 12-month and 18-month landmarks in the cohort 2, with the adjusted hazard ratios 0.52 (95% CI 0.37-0.73) and 0.45 (95% 0.31-0.64) respectively. Conclusion This is the first retrospective study that showed early treatment with amantadine compared with either anticholinergics or MAOBIs may be associated with a reduced risk for LID. However, well-designed randomized clinical trials are needed to further confirm the study finding and determine the optimal duration of amantadine treatment that would exert the most clinical benefit on delaying the onset of dyskinesia. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:32:31Z (GMT). No. of bitstreams: 1 ntu-106-R04451006-1.pdf: 1991233 bytes, checksum: e2aeefacdfc5e9b26d0cd60e235c0d47 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 中文摘要 II
ABSTRACT V LIST OF FIGURES VIII LIST OF TABLES IX LIST OF APPENDIX XI CHAPTER 1. INTRODUCTION 1 CHAPTER 2. LITERATURE REVIEW 4 2.1 Parkinson’s disease 4 2.2 Pharmacological treatment for Parkinson’s disease 8 2.3 Levodopa-induced dyskinesia 10 2.4 Neuroprotective effect of Amantadine 15 CHAPTER 3. METHODS 17 3.1 Data source 17 3.2 Study design and study population 17 3.3 Amantadine-exposed cohort and active comparator 19 3.4 Follow-up time and outcome definition 19 3.5 Baseline characteristics and covariates 20 3.6 Statistical analysis 21 3.7 Sensitivity analysis 22 CHAPTER 4. RESULTS 24 4.1 Study Population 24 4.2 Cohort 1: Amantadine vs. Anticholinergics 25 4.3 Cohort 2: Amantadine vs. MAOBIs 30 CHAPTER 5. DISUCSSION 36 5.1 Association between early use of amantadine and LID 36 5.2 Unknown drug exposure history and risk of LID 38 5.3 Motor subtypes and risk of LID 40 5.4 Age and risk of LID 44 5.5 Strengths and limitations 46 CHAPTER 6. CONCLUSSION 48 FIGURES 49 TABLES 54 REFERENCE 75 APPENDIX 83 | |
dc.language.iso | zh-TW | |
dc.title | 巴金森氏病早期使用amantadine治療與左旋多巴誘發異動症的發病時間相關性探討 | zh_TW |
dc.title | Association between Early Treatment with Amantadine and the Onset of Levodopa-Induced Dyskinesia in Patient with Parkinson’s Disease | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 吳瑞美(Ruey-Meei Wu) | |
dc.contributor.oralexamcommittee | 林芳如(Fang-Ju Lin) | |
dc.subject.keyword | 巴金森氏病,異動症,金剛烷胺,界標分析,神經保護, | zh_TW |
dc.subject.keyword | Parkinson’s disease,levodopa-induced dyskinesia,amantadine,landmark analysis,neuroprotection, | en |
dc.relation.page | 87 | |
dc.identifier.doi | 10.6342/NTU201702336 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 1.94 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。